Press releases

December 10, 2014 Invitae and collaborators present data at San Antonio Breast Cancer Symposium demonstrating use of multi-gene panels for reliable risk assessment in hereditary breast/ovarian cancer patients
Invitae’s platform demonstrates high concordance with traditional diagnostic tests for BRCA1 and BRCA2 and increased yield of clinical findings in hereditary cancer risk assessment. SAN ANTONIO – December 10, 2014 – Invitae Corporation, a genetic information company, announced the presentation of two scientific studies at the 37th Annual San Antonio Breast Cancer Symposium: “Clinical Evaluation of Multi-gene Testing for Hereditary Breast and Ovarian Cancer” (Poster P4-12-04) and “Technical Evaluation of Multi-gene Testing for Heredity Breast and Ovarian Cancer” (Poster P4-12-07).  The studies were both conducted in collaboration with the Massachusetts General Hospital and the Stanford University Cancer Institute and utilized Invitae’s next generation sequencing (NGS) based 29-gene hereditary cancer panel. This panel includes BRCA1 and BRCA2, as well as 27 other important genes related to hereditary cancer syndromes. Between these two studies, the Invitae multi-gene test panel was
Read more
December 3, 2014 Invitae announces reimbursement coverage decision by Blue Shield of California and acceptance as a Medicare provider
SAN FRANCISCO, December 3, 2014 – Invitae Corporation, a genetic information company, announced that its testing services are eligible for coverage by two additional payors, Blue Shield of California and the Centers for Medicare and Medicaid Services (CMS).  “Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” said Lisa Alderson, chief commercial officer of Invitae.  “Since launching just over a year ago, we have grown our volume rapidly by offering high quality genetic testing at an affordable price for payors.” Currently, Invitae offers clinicians an assay of 216 genes comprising 85 different genetic disorders and 17 targeted panels focused on hereditary cancers, including breast, ovarian, colon and pancreatic cancer, as well as cardiology, hematology, neurology and pediatric panels.  Invitae currently allows physicians a free re-requisition of additional data within
Read more
December 2, 2014 Invitae receives accreditation for its laboratory from the College of American Pathologists
SAN FRANCISCO, December 2, 2014 – Invitae Corporation, a genetic information company, announced that it has received accreditation from the College of American Pathologists (CAP).  The CAP accreditation is awarded to facilities that meet the highest standards of quality in laboratory services. According to the Commission on Laboratory Accreditation, the U.S. government recognizes the CAP Laboratory Accreditation Program, which began in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.  During the CAP accreditation process, inspectors perform an on-site inspection and examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, as well as overall management.  "Receiving CAP accreditation is an important recognition of our laboratory as we continue to advance our goal to
Read more
October 13, 2014 Invitae Completes $120 Million Series F Financing
SAN FRANCISCO, October 13, 2014 – Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence.  New investors participating in the round included (in alphabetical order) The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock Springs Capital and Wellington Management Company, LLP, among others.  Existing investors participating in the financing included Casdin Capital, Genesys Capital, Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Redmile Group and Thomas McNerney & Partners, among others. J.P. Morgan Securities LLC acted as sole placement agent on the financing. About Invitae Corporation Invitae, based in San Francisco, is a genetic information company whose mission is to bring genetic information into
Read more
August 12, 2014 Invitae Offers PALB2 Testing, Providing Clinicians with a Reliable, Fast, Affordable Option for Patients
SAN FRANCISCO - August 12, 2014 - Invitae Corporation, a genetic information company, offers PALB2 testing, providing clinicians with a reliable, fast and affordable option for their cancer patients. Available with a turnaround time of approximately three weeks, the test includes full gene sequencing and deletion/duplication analysis. The test is globally available and is priced at $1,500 in the United States. A recent multinational study provides compelling evidence that PALB2 is a high-risk breast cancer susceptibility gene (Antoniu et al, N Engl J Med 2014; 371:497-506; DOI: 10.1056/NEJMoa1400382). This landmark study estimates the lifetime breast cancer risk for female carriers of truncating mutations in this gene to be between 33%–58%, depending on the specific family history of the patient. Due to the high lifetime risk for breast cancer in PALB2 loss-of-function mutation carriers, the authors support the inclusion of PALB2 when testing patients from high-risk breast cancer
Read more
July 30, 2014 Invitae and Nanopharmacia Announce Partnership to Make Reliable, Fast and Affordable Hereditary Cancer Genetic Testing Broadly Available in Mexico
- Partnership Expands Invitae’s Global Presence into Mexico, Costa Rica, & Panama - SAN FRANCISCO and MEXICO CITY― July 30, 2014 ― Invitae Corporation, a genetic information company, and Nanopharmacia, the leading oncology molecular test provider in Mexico, today announced an exclusive partnership to make Invitae’s genetic tests for the management of hereditary cancers broadly available throughout Mexico.  In addition, the partnership includes access on a non-exclusive basis in Costa Rica and Panama.  Nanopharmacia will offer Invitae’s hereditary cancer panels and BRCA1/BRCA2 offering to a  wide network of onco-geneticists and medical and surgical oncologists. Invitae’s oncology offering  includes the following: Single gene BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis High-risk hereditary breast cancer panel (6 genes) Women’s hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer)
Read more
June 12, 2014 Invitae Offers Multi-Gene Testing for Hereditary Pancreatic Cancer, Providing Clinicians with a Reliable, Fast, Affordable Option for Patients
SAN FRANCISCO, June 12, 2014 – Invitae Corporation , a genetic information company, today announced that it now offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast and affordable option for their cancer patients and their families. With results typically available within three weeks, this panel includes an analysis of 17 genes and currently is the most comprehensive panel available. The test is available globally and at a contracted price of $1,500 in the United States. The new Invitae Hereditary Pancreatic Cancer Panel covers the genetic associations most commonly linked to an increased risk of pancreatic cancer and includes the following genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PALLD, PMS2, STK11, TP53 and VHL. In addition, Invitae offers hereditary pancreatitis genes CFTR and SPINK1, which some providers choose when assessing a patient for hereditary pancreatic cancer. These genes can
Read more
April 14, 2014 Invitae’s Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Data published in Journal of Clinical Oncology from research collaboration with Stanford University - SAN FRANCISCO, April 14, 2014 – Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment. Titled, “Clinical Evaluation of a Multiple-Gene Sequencing Panel,” the first author of the manuscript is Allison W. Kurian, MD, MSc, assistant professor of medicine and of health research and policy at Stanford, and the senior author is James Ford , M.D., associate professor of medicine (oncology), pediatrics (medical genetics) and of genetics and director of the  Stanford Cancer Genetics Clinic .
Read more
January 13, 2014 Invitae Announces the Availability of its Family History Tool – A Free Family History Collection App – on Apple’s App Store
SAN FRANCISCO, January 13, 2014 – Invitae Corporation , a diagnostic genetic information company, today announced that the “Invitae Family History Tool” is now available.  It is a free family history collection app that enables genetic counselors to digitally build, modify, share, and save their patients’ pedigrees.  Available as an iPad and a web app, both versions can be accessed by visiting www.invitae.com/en/family-history/ or by downloading the iPad app directly from Apple ’s App Store . The Invitae Family History Tool enables genetic counselors to build detailed and comprehensive pedigrees quickly and simply with a user-friendly interface, replacing cumbersome paper pedigrees.  A web-based version is also available that seamlessly syncs with the iPad app in order to accommodate use on tablets, laptops, and desktop computers. All patient data is safely and securely stored on a HIPAA-compliant server. “Historically, the development of genetic pedigrees have been
Read more
January 10, 2014 Invitae Announces Sean George to Participate in Gene Panel during 32nd Annual J.P. Morgan Healthcare Conference
Panel Titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine” SAN FRANCISCO, January 10, 2014 – Invitae Corporation, a genetic diagnostics company, today announced that Sean George, co-founder of Invitae, is scheduled to speak on a panel titled, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine” during the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 at 5:00 pm PST in San Francisco.  A live, listen-only webcast of the presentation can be accessed by visiting  http://jpmorgan.metameetings.com/confbook/healthcare14/directlink?p=14095 . About Invitae Corporation Invitae's mission is to reinvent genetic testing by making it more affordable and accessible than ever before. Invitae hopes to lead the way from an era of genetic scarcity to genetic abundance to significantly improve healthcare worldwide. 
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 7.03 +0.00 +0% Volume: 1,128,069 20 minute delay January 19, 2018

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com